LeMaitre Vascular (NASDAQ:LMAT) Receives New Coverage from Analysts at KeyCorp

Research analysts at KeyCorp assumed coverage on shares of LeMaitre Vascular (NASDAQ:LMATGet Free Report) in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage set a “sector weight” rating on the medical instruments supplier’s stock.

Several other equities research analysts have also commented on LMAT. JMP Securities initiated coverage on LeMaitre Vascular in a research note on Monday, October 23rd. They set an “outperform” rating and a $60.00 price target on the stock. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday, January 31st. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $67.60.

Check Out Our Latest Stock Report on LMAT

LeMaitre Vascular Trading Down 1.6 %

Shares of LMAT opened at $59.28 on Tuesday. The stock’s 50 day moving average is $56.20 and its two-hundred day moving average is $55.14. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $68.67. The firm has a market capitalization of $1.32 billion, a PE ratio of 48.99, a P/E/G ratio of 2.88 and a beta of 0.86.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 24,869 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $54.71, for a total transaction of $1,360,582.99. Following the transaction, the chief executive officer now owns 2,312,857 shares of the company’s stock, valued at approximately $126,536,406.47. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO George W. Lemaitre sold 24,869 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $54.71, for a total value of $1,360,582.99. Following the sale, the chief executive officer now directly owns 2,312,857 shares of the company’s stock, valued at $126,536,406.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 22,288 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $54.42, for a total transaction of $1,212,912.96. Following the transaction, the chief executive officer now directly owns 2,269,475 shares of the company’s stock, valued at approximately $123,504,829.50. The disclosure for this sale can be found here. 12.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LMAT. Citigroup Inc. raised its holdings in LeMaitre Vascular by 6.6% in the first quarter. Citigroup Inc. now owns 20,987 shares of the medical instruments supplier’s stock valued at $975,000 after buying an additional 1,293 shares during the period. MetLife Investment Management LLC grew its stake in shares of LeMaitre Vascular by 58.0% in the first quarter. MetLife Investment Management LLC now owns 12,092 shares of the medical instruments supplier’s stock valued at $562,000 after buying an additional 4,441 shares in the last quarter. Rhumbline Advisers grew its stake in shares of LeMaitre Vascular by 8.2% in the first quarter. Rhumbline Advisers now owns 95,806 shares of the medical instruments supplier’s stock valued at $4,452,000 after buying an additional 7,266 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of LeMaitre Vascular by 14.1% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,567 shares of the medical instruments supplier’s stock valued at $770,000 after buying an additional 2,042 shares during the period. Finally, BlackRock Inc. boosted its holdings in LeMaitre Vascular by 0.9% in the 1st quarter. BlackRock Inc. now owns 3,175,432 shares of the medical instruments supplier’s stock worth $147,562,000 after acquiring an additional 28,008 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

See Also

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.